EA201171098A1 - 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина - Google Patents

8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина

Info

Publication number
EA201171098A1
EA201171098A1 EA201171098A EA201171098A EA201171098A1 EA 201171098 A1 EA201171098 A1 EA 201171098A1 EA 201171098 A EA201171098 A EA 201171098A EA 201171098 A EA201171098 A EA 201171098A EA 201171098 A1 EA201171098 A1 EA 201171098A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
disorders
quinolines
substitute
sirtuinmodulating
Prior art date
Application number
EA201171098A
Other languages
English (en)
Inventor
Чи Б. Ву
Ребекка Л. Касаубон
Original Assignee
Сертрис Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сертрис Фармасьютикалз, Инк. filed Critical Сертрис Фармасьютикалз, Инк.
Publication of EA201171098A1 publication Critical patent/EA201171098A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к 8-замещенным хинолинам и родственным аналогам в качестве сиртуинмодулирующих соединений структурной формулы (I) и способам их применения. Сиртуинмодулирующие соединения можно применять для увеличения продолжительности жизни клетки и лечения и/или предотвращения широкого спектра заболеваний и расстройств, включая, например, заболевания или расстройства, связанные со старением или стрессом, диабет, ожирение, нейродегенеративные заболевания, сердечно-сосудистое заболевание, коагулопатию, воспаление, рак и/или гиперемию, а также заболевания или расстройства, при которых будет полезна повышенная митохондриальная активность. Также настоящее изобретение относится к композициям, содержащим сиртуинмодулирующее соединение в комбинации с другим терапевтическим агентом.
EA201171098A 2009-03-02 2010-03-02 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина EA201171098A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15674909P 2009-03-02 2009-03-02
PCT/US2010/025963 WO2010101949A1 (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
EA201171098A1 true EA201171098A1 (ru) 2012-04-30

Family

ID=42709991

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171098A EA201171098A1 (ru) 2009-03-02 2010-03-02 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина

Country Status (11)

Country Link
EP (1) EP2403833A4 (ru)
JP (1) JP2012519211A (ru)
KR (1) KR20110128908A (ru)
CN (1) CN102414180A (ru)
AU (1) AU2010221417A1 (ru)
BR (1) BRPI1011477A2 (ru)
CA (1) CA2754058A1 (ru)
EA (1) EA201171098A1 (ru)
IL (1) IL214943A0 (ru)
MX (1) MX2011009213A (ru)
WO (1) WO2010101949A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2669943C2 (ru) * 2013-07-29 2018-10-17 Ф. Хоффманн-Ля Рош Аг Производные 1,7-нафтиридин-3-карбоксамида, полезные в качестве нейрогенных агентов

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012010A (es) 2008-05-01 2010-11-30 Sirtris Pharmaceuticals Inc Quinolinas y analogos relacionados como moduladores de sirtuin.
AU2009266889B2 (en) 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
CA2738809C (en) 2008-09-29 2015-11-24 Sirtris Pharmaceuticals, Inc. Quinazolinone, quinolone and related analogs as sirtuin modulators
WO2011059839A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
ES2564972T3 (es) 2011-03-18 2016-03-30 Bayer Intellectual Property Gmbh Derivados de N-(3-carbamoilfenil)-1H-pirazol-5-carboxamida y su uso para combatir parásitos animales
CN102250151B (zh) * 2011-05-17 2013-11-06 中国科学院化学研究所 2-芳亚胺-8-苯并咪唑喹啉过渡金属配合物及其制备方法与应用
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
RU2014120168A (ru) * 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические азагетероциклы и аналоги в качестве модуляторов сиртуина
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
EA201491667A1 (ru) 2012-03-13 2015-03-31 Басф Се Фунгицидные соединения пиримидина
CN104812387A (zh) 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 取代的1,6-萘啶
EP2970272B1 (en) * 2013-03-14 2019-02-27 Merck Patent GmbH Glycosidase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2914100A1 (en) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
JP6112724B2 (ja) * 2013-10-31 2017-04-12 日本化薬株式会社 １，５−ナフチリジン誘導体およびそれを有効成分として含んでなる殺虫剤
UA117041C2 (uk) 2013-11-12 2018-06-11 Ф. Хоффманн-Ля Рош Аг ПІРИДО[4,3-b]ПІРАЗИН-2-КАРБОКСАМІДИ ЯК НЕЙРОГЕННІ ЗАСОБИ ДЛЯ ЛІКУВАННЯ НЕЙРОДЕГЕНЕРАТИВНИХ РОЗЛАДІВ
TW201612161A (en) 2014-01-20 2016-04-01 Bayer Cropscience Ag Quinoline derivatives as insecticides and acaricides
CN106459090A (zh) 2014-02-19 2017-02-22 拜耳制药股份公司 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶
ES2620751T3 (es) 2014-05-23 2017-06-29 Active Biotech Ab Nuevos compuestos útiles como inhibidores de S100
US20160016951A1 (en) * 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
SG10201900631TA (en) 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
EP3868752A1 (en) 2014-08-28 2021-08-25 Asceneuron SA Glycosidase inhibitors
CN107001361A (zh) 2014-12-02 2017-08-01 拜耳医药股份有限公司 杂芳基取代的咪唑并[1，2‑a]吡啶及其用途
CN104592109A (zh) * 2015-01-19 2015-05-06 湖南华腾制药有限公司 一种8-溴喹啉衍生物的制备方法
EA201791781A1 (ru) * 2015-02-11 2018-02-28 Базилеа Фармацойтика Интернациональ Аг Производные замещенного моно- и полиазанафталина и их применение
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
MA43677A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
EP3419972B1 (en) 2016-02-25 2023-07-26 Asceneuron SA Glycosidase inhibitors
CN109071526B (zh) 2016-02-25 2023-02-28 阿森纽荣股份公司 哌嗪衍生物的酸加成盐
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
BR112021017049A2 (pt) * 2019-02-28 2022-02-08 Kezar Life Sciences Derivados de tiazol como inibidores de secreção de proteínas
CN110964011B (zh) * 2019-12-16 2022-06-21 诚达药业股份有限公司 一种8-氯-1,7-萘啶-3-甲醛的合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
WO2024059216A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2024059212A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same
CN117362286B (zh) * 2023-12-08 2024-03-12 清华大学 具有sirt6激动活性的化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69818094T2 (de) * 1997-12-11 2004-07-08 Biochem Pharma Inc., Laval Antivirale verbindungen
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
MXPA05009722A (es) * 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
MX2007001267A (es) * 2004-08-03 2007-07-11 Serenex Inc Derivados de naftiridinas 2,8-disustituidas.
CA2599992A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
US20120094958A1 (en) * 2008-02-28 2012-04-19 Novartis Ag Quinolines as inhibitors of farnesyl pyrophosphate synthase
MX2010012010A (es) * 2008-05-01 2010-11-30 Sirtris Pharmaceuticals Inc Quinolinas y analogos relacionados como moduladores de sirtuin.
CA2738809C (en) * 2008-09-29 2015-11-24 Sirtris Pharmaceuticals, Inc. Quinazolinone, quinolone and related analogs as sirtuin modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2669943C2 (ru) * 2013-07-29 2018-10-17 Ф. Хоффманн-Ля Рош Аг Производные 1,7-нафтиридин-3-карбоксамида, полезные в качестве нейрогенных агентов

Also Published As

Publication number Publication date
CA2754058A1 (en) 2010-09-10
JP2012519211A (ja) 2012-08-23
BRPI1011477A2 (pt) 2016-03-22
MX2011009213A (es) 2011-12-14
EP2403833A4 (en) 2012-08-29
EP2403833A1 (en) 2012-01-11
KR20110128908A (ko) 2011-11-30
IL214943A0 (en) 2011-11-30
WO2010101949A1 (en) 2010-09-10
AU2010221417A1 (en) 2011-09-22
CN102414180A (zh) 2012-04-11

Similar Documents

Publication Publication Date Title
EA201171098A1 (ru) 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина
EA201170137A1 (ru) Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина
EA201170847A1 (ru) Тиазолопиридиновые соединения, регулирующие сиртуин
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
EP2342188A4 (en) CHROMENONE ANALOGUES AS MODULATORS OF SIRTUIN
EA201071263A1 (ru) Хинолины и их аналоги в качестве модуляторов сиртуина
EA201070551A1 (ru) Сиртуинмодулирующие соединения
MX2011006475A (es) Ftalazinona y analogos relacionados como moduladores de sirtuina.
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
AU2014265671A8 (en) Substituted bridged urea analogs as sirtuin modulators
EA201070034A1 (ru) Модулирующие сиртуин производные имидазотиазола
EA201070579A1 (ru) Солюбилизированные тиазолопиридины
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
IN2012DN03799A (ru)
EA201690899A1 (ru) Оксазепины в качестве модуляторов ионных каналов
MX2009013977A (es) Compuestos de tiazolopiridina moduladores de sirtuinas.
EA201790417A3 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
EA201070158A1 (ru) Сульфонамиды в качестве trpm8 модуляторов
EA201391532A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201500175A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201791074A1 (ru) Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина
EA201690972A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов